盐酸贝洛替康(Belotecan Hydrochloride) - 药物靶点：Top I_在研适应症：宫颈癌，非小细胞肺癌，卵巢癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Belotecan、Belotecan hydrochloride (USAN)、Camtobell

+ [6]

靶点

Top I

作用方式

抑制剂

作用机制

TOP1抑制剂(DNA拓扑异构酶I抑制剂)

治疗领域

肿瘤内分泌与代谢疾病呼吸系统疾病+ [1]

在研适应症

宫颈癌非小细胞肺癌卵巢癌+ [1]

非在研适应症

广泛期小细胞肺癌转移性非小细胞肺癌卵巢上皮癌+ [3]

原研机构

Chong Kun Dang Pharmaceutical Corp.

在研机构

Chong Kun Dang Pharmaceutical Corp.

非在研机构-

最高研发阶段批准上市

首次获批日期

韩国 (2003-10-22),

卵巢癌小细胞肺癌

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C25H27N3O4

InChIKeyLNHWXBUNXOXMRL-VWLOTQADSA-N

CAS号256411-32-2

查看全部结构式(2)

关联

8

项与盐酸贝洛替康相关的临床试验

KCT0004484

/ Recruiting临床2期IIT

Phase II study of Belotecan monotherapy in patients with recurrent or persistent cervical cancer

开始日期2020-09-17

申办/合作机构-

NCT01784107

/ Unknown status临床1/2期IIT

A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer

Phase 1 : To evaluate MTD(Maximal tolerated dose)and DLT(Dose limiting Toxicity) of Belotecan and Ifosfamide.
Phase 2 : To analyse efficacy and toxicity of Belotecan and Ifosfamide.

开始日期2011-07-01

申办/合作机构

Gachon University Gil Medical Center

NCT01630018

/ Completed临床2期

A Phase Ⅱb, Randomized, Open, Parallel-Group, Multi-Center Trial to Assess the Efficacy and Safety of Belotecan(CamtoBell Inj.) or Topotecan in Patients With Recurrent or Refractory Ovarian Cancer

The purpose of this study is to determine the efficacy and safety of belotecan or topotecan in patients with recurrent or refractory ovarian cancer (AOC).

开始日期2011-01-01

申办/合作机构

Chong Kun Dang Pharmaceutical Corp.

100 项与盐酸贝洛替康相关的临床结果

登录后查看更多信息

100 项与盐酸贝洛替康相关的转化医学

登录后查看更多信息

100 项与盐酸贝洛替康相关的专利（医药）

登录后查看更多信息

141

项与盐酸贝洛替康相关的文献（医药）

2025-03-01·European Journal of Medicinal Chemistry

Repurposing FDA-approved drugs to target G-quadruplexes in breast cancer

Article

作者: Marzano, Simona ; Randazzo, Antonio ; Landolfi, Laura ; Catalanotti, Bruno ; Malfitano, Anna Maria ; Pagano, Bruno ; Moraca, Federica ; Castellano, Giuliano ; Napolitano, Fabiana ; Arciuolo, Valentina ; Di Porzio, Anna ; D'Aria, Federica ; Amato, Jussara

Breast cancer, a leading cause of cancer-related mortality in women, is characterized by genomic instability and aberrant gene expression, often influenced by noncanonical nucleic acid structures such as G-quadruplexes (G4s). These structures, commonly found in the promoter regions and 5'-untranslated RNA sequences of several oncogenes, play crucial roles in regulating transcription and translation. Stabilizing these G4 structures offers a promising therapeutic strategy for targeting key oncogenic pathways. In this study, we employed a drug repurposing approach to identify FDA-approved drugs capable of binding and stabilizing G4s in breast cancer-related genes. Using ligand-based virtual screening and biophysical methods, we identified several promising compounds, such as azelastine, belotecan, and irinotecan, as effective G4 binders, with significant antiproliferative effects in breast cancer cell lines. Notably, belotecan and irinotecan exhibited a synergistic mechanism, combining G4 stabilization with their established topoisomerase I inhibition activity to enhance cytotoxicity in cancer cells. Our findings support the therapeutic potential of G4 stabilization in breast cancer, validate drug repurposing as an efficient strategy to identify G4-targeting drugs, and highlight how combining G4 stabilization with other established drug activities may improve anticancer efficacy.

2024-03-01·Journal of Controlled Release

Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker

Article

作者: Liubomirski, Yulia ; Satchi-Fainaro, Ronit ; Shan, Min ; Deutsch, Carl ; Kalimi, Doron ; Berger, Nir ; Shelef, Omri ; Scomparin, Anna ; Yeini, Eilam ; Gholap, Sachin ; Tonillo, Jason ; Sweeney-Lasch, Stanley ; Shabat, Doron ; Das, Sayantan ; Ge, Liang ; Dickgiesser, Stephan ; Toister-Achituv, Mira ; Tiram, Galia ; Zauberman, Arie ; Schröter, Christian ; Gnaim, Samer

Antibody-drug conjugates (ADCs) are a rapidly expanding class of anticancer therapeutics, with 14 ADCs already approved worldwide. We developed unique linker technologies for the bioconjugation of drug molecules with controlled-release applications. We synthesized cathepsin-cleavable ADCs using a dimeric prodrug system based on a self-immolative dendritic scaffold, resulting in a high drug-antibody ratio (DAR) with the potential to reach 16 payloads due to its dendritic structure, increased stability in the circulation and efficient release profile of a highly cytotoxic payload at the targeted site. Using our novel cleavable linker technologies, we conjugated the anti-human epidermal growth factor receptor 2 (anti-HER2) antibody, trastuzumab, with topoisomerase I inhibitors, exatecan or belotecan. The newly synthesized ADCs were tested in vitro on mammary carcinoma cells overexpressing human HER2, demonstrating a substantial inhibitory effect on the proliferation of HER2-positive cells. Importantly, a single dose of our trastuzumab-based ADCs administered in vivo to mice bearing HER2-positive tumors, showed a dose-dependent inhibition of tumor growth and survival benefit, with the most potent antitumor effects observed at 10 mg/kg, which resulted in complete tumor regression and survival of 100% of the mice. Overall, our novel dendritic technologies using the protease-cleavable Val-Cit linker present an opportunity for the development of highly selective and potent controlled-released therapeutic payloads. This strategy could potentially lead to the development of novel and effective ADC technologies for patients diagnosed with HER2-positive cancers. Moreover, our proposed ADC linker technology can be implemented in additional medical conditions such as other malignancies as well as autoimmune diseases that overexpress targets, other than HER2.

2024-01-01·In Vivo

Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian Cancer

Article

作者: Kim, Se Ik ; Park, Noh Hyun ; Kim, Hee Seung ; Chung, Hyun Hoon ; Yoon, Hee Yeun ; Lee, Maria ; Song, Yong Sang ; Seol, Aeran

BACKGROUND/AIMOver the past several decades, new anti-cancer drugs have been developed for the treatment of epithelial ovarian cancer. The development of drugs has led to changes in improving the prognosis of ovarian cancer patients. One of these drugs, bevacizumab, is used for advanced or recurrent ovarian cancer. In this study, we aimed to evaluate survival improvement in patients with platinum-resistant relapsed epithelial ovarian cancer (PR-ROC) after introduction of bevacizumab in real world experience.PATIENTS AND METHODSWe retrospectively divided patients with PR-ROC into two groups: bevacizumab plus chemotherapy (BEV-CT group) and chemotherapy alone (CT group). Progression-free survival (PFS), the primary endpoint, between two groups was compared to evaluate whether survival outcomes were improved. In addition, overall survival (OS) was also compared.RESULTSA total of 154 patients were included in the study: 57 and 97 patients in the BEV-CT and CT groups, respectively. OS was significantly longer in the BEV-CT group than in the CT group. The use of bevacizumab was identified as a favorable prognostic factor for OS. In a subgroup analysis confined to second-line chemotherapy, PFS and OS were statistically different between groups. More patients in the CT group suffered hematologic adverse events of grade 3 or above than patients in the BEV-CT group.CONCLUSIONIn a real-world clinical setting, introduction of bevacizumab led to improvement of OS in patients with PR-ROC with a tolerable toxicity.

42

项与盐酸贝洛替康相关的新闻（医药）

2025-03-10

·研发客

科伦博泰芦康沙妥珠单抗第二项适应症获批上市用于治疗EGFR突变非小细胞肺癌 | 新闻稿

2025年3月10日，四川科伦博泰生物医药股份有限公司（下称“科伦博泰”或“公司” 6990.HK）靶向人滋养细胞表面抗原2(TROP2)的抗体药物偶联物(ADC)芦康沙妥珠单抗(sac-TMT，前称SKB264/MK-2870)(佳泰莱®)获国家药品监督管理局(NMPA)批准第二个适应症,用于治疗经表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)和含铂化疗治疗后进展的EGFR基因突变阳性的局部晚期或转移性非鳞状非小细胞肺癌(NSCLC)成人患者。这是全球首个在肺癌适应症获批上市的TROP2 ADC药物。与目前标准治疗相比，芦康沙妥珠单抗(sac-TMT)显著延长此类患者的总生存获益。本次批准是基于一项多中心、随机、对照关键临床研究(OptiTROP-Lung03),评估芦康沙妥珠单抗(sac-TMT)单一疗法每两周(Q2W)5mg/kg静脉注射对比多西他赛用于治疗经EGFR-TKI和含铂化疗治疗(序贯或联合)失败后的局部晚期或转移性EGFR突变NSCLC患者的有效性和安全性。在预设的期中分析结果显示，与多西他赛相比，芦康沙妥珠单抗(sac-TMT)单一疗法在客观缓释率(ORR)、无进展生存期(PFS)和总生存期(OS)方面具有显著统计学意义和临床意义的改善。这也是全球首个创新ADC药物，在针对EGFR-TKI和含铂化疗失败后EGFR突变型NSCLC患者上，与标准治疗对比，显示出具有统计学和临床意义显著改善的总生存获益。此前，NMPA已批准芦康沙妥珠单抗(sac-TMT)用于治疗既往至少接受过2种系统治疗（其中至少1种治疗针对晚期或转移性阶段）的不可切除的局部晚期或转移性三阴性乳腺癌；并已受理一项芦康沙妥珠单抗(sac-TMT)单药治疗经EGFR-TKI治疗失败的EGFR突变NSCLC患者的补充新药申请(sNDA)。目前，芦康沙妥珠单抗（sac-TMT）在NSCLC领域全面布局，默沙东与科伦博泰在全球及中国共开展10项NSCLC注册性III期临床研究，覆盖从后线晚期到术后辅助早期，包括单药和联合用药研究。其中，已在中国开展联合奥西替尼一线治疗EGFR突变的局部晚期或转移性NSCLC的注册性III期临床研究（OptiTROP-Lung07）。科伦博泰首席执行官葛均友博士表示，“非常高兴公司TROP2 ADC芦康沙妥珠单抗（佳泰莱®）第二项适应症获批上市，这是我们在肺癌领域取得的重大创新突破。本次新适应症的成功获批，将填补国内EGFR突变NSCLC后线治疗空白，惠及更多恶性肿瘤患者。科伦博泰始终坚持创新引领，未来，公司将继续深耕ADC领域，加速多瘤种适应症拓展，依托国际化合作，让更多的创新药物惠及全球患者。” 关于芦康沙妥珠单抗（sac-TMT , 佳泰莱®）作为本公司的核心产品，芦康沙妥珠单抗(sac-TMT)是一款本公司拥有自主知识产权的新型TROP2 ADC，针对NSCLC、乳腺癌(BC)、胃癌(GC)、妇科肿瘤等晚期实体瘤。芦康沙妥珠单抗(sac-TMT)采用新型连接子进行开发，其通过偶联一种贝洛替康衍生的拓扑异构酶I抑制剂作为有效载荷，药物抗体比(DAR)达到7.4。芦康沙妥珠单抗(sac-TMT)通过重组抗TROP2人源化单克隆抗体特异性识别肿瘤细胞表面的TROP2，其后被肿瘤细胞内吞并于细胞内释放KL610023。KL610023作为拓扑异构酶I抑制剂，可诱导肿瘤细胞DNA损伤，进而导致细胞周期阻滞及细胞凋亡。此外，其亦于肿瘤微环境中释放KL610023。鉴于KL610023具有细胞膜渗透性，其可实现旁观者效应，即杀死邻近的肿瘤细胞。于2022年5月，本公司授予默沙东(美国新泽西州罗威市默克公司的商号)在大中华区(包括中国内地、香港、澳门及台湾)以外的所有地区开发、使用、制造及商业化芦康沙妥珠单抗(sac-TMT)的独家权利。关于非小细胞肺癌（NSCLC）肺癌是全球第二大常见癌症，主要包括非小细胞肺癌（NSCLC）和小细胞肺癌（SCLC），其中NSCLC是最常见的病理类型，约占所有肺癌总数的80%~85%。我国NSCLC患者分子分型不同于西方人群，EGFR突变是常见的变异基因类型，约占我国肺腺癌患者的40%-50%。根据2024 CSCO指南，IV期EGFR突变NSCLC首选EGFR-TKIs治疗[1]；EGFR-TKIs治疗耐药后含铂化疗是目前主要的一线化疗方案；对于EGFR-TKIs及含铂化疗失败的人群现有治疗方案疗效欠佳，存在较大未被满足的临床需求，亟需新药改善患者生存。参考文献 [1] [中国临床肿瘤学会(CSCO)(2024)]非小细胞肺癌诊疗指南. 关于科伦博泰四川科伦博泰生物医药股份有限公司（简称“科伦博泰生物”，股票代码：6990.HK）是科伦药业控股子公司，专注于创新生物技术药物及小分子药物的研发、生产、商业化及国际合作。公司围绕全球和中国未满足的临床需求，重点布局肿瘤、自身免疫、炎症和代谢等重大疾病领域，建设国际化药物研发与产业化平台，致力于成为在创新药物领域国际领先的企业。公司目前拥有30余个重点创新药项目，其中3个项目已获批上市，1个项目处于NDA阶段，10余个项目正处于临床阶段。公司成功构建了享誉国际的专有ADC开发平台OptiDCTM，已有1个ADC项目获批上市，1个ADC项目处于NDA阶段，多个ADC或新型ADC项目处于临床或临床前研究阶段。更多信息请访问官网https://kelun-biotech.com/。

抗体药物偶联物上市批准临床3期引进/卖出申请上市

2025-03-10

·同写意

全球首个！这款TROP2 ADC药物获批肺癌适应症

抗体药物偶联物临床3期上市批准申请上市引进/卖出

2025-03-10

·PRNewswire

Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC

CHENGDU, China, March 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) was approved for marketing by the National Medical Products Administration (NMPA) for the second indication which is for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy. This is the first TROP2 ADC drug approved for marketing in lung cancer globally. Compared with current standard of care, sac-TMT significantly extents the overall survival benefits of these patients. The approval is based on a multi-center, randomized, controlled, pivotal study (OptiTROP-Lung03) that evaluates the efficacy and safety profile of sac-TMT monotherapy 5mg/kg every other week (Q2W) as an intravenous injection versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have failed after treatment with an EGFR-TKI and platinum-based chemotherapy (used sequentially or in combination). As demonstrated in a pre-specified interim analysis, sac-TMT monotherapy demonstrated a statistically significant and clinically meaningful improvement in objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) compared with docetaxel. Sac-TMT is also the first ADC drug to demonstrate a statistically and clinically significant improvement in overall survival benefit versus standard of care in patients with EGFR-mutant NSCLC after failure of EGFR-TKI and platinum-based chemotherapy. Previously, the NMPA has approved the marketing of sac-TMT in China for adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) and accepted a supplemental new drug application (sNDA) seeking the approval of sac-TMT monotherapy for patients with EGFR-mutant NSCLC who have failed after EGFR-TKI therapy. Currently, sac-TMT is fully deployed in the NSCLC field, and Merck Sharp & Dohme and the company are conducting a total of 10 registrational Phase Ⅲ clinical studies in NSCLC globally and in China, with the threads covering from the late backline to early postoperative adjuvant, including monotherapy and combination studies. Among them, a registrational Phase Ⅲ clinical study has been conducted in China in combination with osimertinib for the first-line treatment of locally advanced or metastatic NSCLC with EGFR mutations (OptiTROP-Lung07). Dr. Michael Ge, CEO of Kelun-Biotech said, "We are very pleased that the second indication of the Company's TROP2 ADC sacituzumab tirumotecan has been approved for marketing, which is exciting progress for us in the field of lung cancer. The successful approval of this new indication will help to address an unmet treatment need for patients with later-stage EGFRm NSCLC in China. Kelun-Biotech has always been committed to promoting innovation and leadership, and we look forward to continuing our research in the field of ADCs in partnership with MSD." About NSCLC Lung cancer, the second most common cancer in the world, includes two main types of cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC is the most common pathological type, accounting for about 80 to 85% of all lung cancers. The molecular typing of NSCLC patients in China is different from that of Western populations, and EGFR mutation is a common variant gene type, accounting for about 40 to 50% of lung adenocarcinoma patients in China. According to the 2024 Chinese Journal of Cancer Research (CSCO) guidelines, EGFR-TKIs are the preferred treatment for stage IV EGFR-mutant NSCLC.1 Platinum-containing chemotherapy is the main first-line chemotherapy regimen after resistance to EGFR-TKIs; and existing treatment regimens are ineffective in those who have failed EGFR-TKIs and platinum-containing chemotherapy. New drugs are urgently needed to improve patient survival. About sac-TMT ( 佳泰莱 ®) Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macau, and Taiwan). About Kelun-Biotech Kelun-Biotech（6990.HK）is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC or novel ADC projects in clinical or preclinical research stage. For more information, please visit . Reference [1]. [Chinese Society of Clinical Oncology (CSCO) (2024)] Guidelines for the diagnosis and treatment of non-small cell lung cancer. SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准抗体药物偶联物临床1期

100 项与盐酸贝洛替康相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03225	盐酸贝洛替康	L01XX68	DB12459

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
宫颈癌	韩国	Chong Kun Dang Pharmaceutical Corp.	2013-12-17
非小细胞肺癌	韩国	Chong Kun Dang Pharmaceutical Corp.	2003-12-10
卵巢癌	韩国	Chong Kun Dang Pharmaceutical Corp.	2003-10-22
小细胞肺癌	韩国	Chong Kun Dang Pharmaceutical Corp.	2003-10-22

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
卵巢上皮癌	临床1期	韩国	Chong Kun Dang Pharmaceutical Corp.	2011-01-01
复发性卵巢癌	临床1期	韩国	Chong Kun Dang Pharmaceutical Corp.	2011-01-01
复发性小细胞肺癌	临床1期	韩国	Chong Kun Dang Pharmaceutical Corp.	2010-09-01
转移性非小细胞肺癌	临床1期	-	Chong Kun Dang Pharmaceutical Corp.	2009-09-01
广泛期小细胞肺癌	临床1期	韩国	Chong Kun Dang Pharmaceutical Corp.	2009-01-01
小细胞癌	临床1期	韩国	Chong Kun Dang Pharmaceutical Corp.	2009-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01497873 (Pubmed \| Med J Aust \| Br J Cancer) 人工标引	临床2期	小细胞肺癌	164	belotecan	(鑰鑰觸獵鑰醖鹽醖淵鏇) = 齋廠獵襯鹽鬱襯鬱鑰衊構選憲齋製淵積醖窪鏇 (齋選齋網觸壓齋鹽鏇簾 ) 更多	积极	2021-02-01
				topotecan	(鑰鑰觸獵鑰醖鹽醖淵鏇) = 憲糧範顧願窪壓鏇願醖構選憲齋製淵積醖窪鏇 (齋選齋網觸壓齋鹽鏇簾 ) 更多
NCT01630018 (Pubmed \| Br J Cancer)	临床2期	复发性卵巢癌	140	Belotecan 0.5 mg/m2	(網獵製廠願築觸顧憲憲) = 糧積鏇範夢鏇鏇遞簾選窪壓範齋製鹽夢窪築壓 (繭製鑰衊廠淵獵獵夢網 ) 更多	积极	2021-01-19
				Topotecan 1.5 mg/m2	(網獵製廠願築觸顧憲憲) = 鹽鏇齋觸壓憲廠窪餘餘窪壓範齋製鹽夢窪築壓 (繭製鑰衊廠淵獵獵夢網 ) 更多
NCT01497873 (WCLC2018)	临床2期	复发性小细胞肺癌二线	148	Belotecan 0.5 mg/m2	(壓憲構網膚網鏇窪鬱夢) = 壓鬱範鹹鏇範構鑰餘鏇獵網憲窪鏇繭選憲襯艱 (鏇築衊鬱選範鹽鏇觸醖, -0.0195 ~ 0.2651) 更多	积极	2018-09-25
				Topotecan 1.5 mg/m2	(壓憲構網膚網鏇窪鬱夢) = 鹽襯衊蓋願鏇餘築觸願獵網憲窪鏇繭選憲襯艱 (鏇築衊鬱選範鹽鏇觸醖 ) 更多
NCT00826644 (Pubmed \| BMC Cancer) 人工标引	临床3期	小细胞肺癌一线	147	Cisplatin+Belotecan	(憲積範願餘膚窪壓齋鬱) = 糧觸淵鹹獵餘壓積淵衊鑰廠簾淵廠鹹鑰選築鬱 (獵鬱窪獵餘餘構窪簾獵 ) 更多	非劣	2016-08-26
				Cisplatin+Etoposide	(憲積範願餘膚窪壓齋鬱) = 鏇遞築鹹餘繭鑰積鬱醖鑰廠簾淵廠鹹鑰選築鬱 (獵鬱窪獵餘餘構窪簾獵 ) 更多
NCT01630018 (ASCO2015)	临床2期	复发性卵巢癌	141	Belotecan 0.5 mg/m2	(鬱鹽餘鏇鬱淵範網糧繭) = 膚憲憲夢醖膚膚蓋積鑰願鏇襯淵獵構遞醖觸鹽 (範膚鹽醖襯觸積鏇蓋廠 ) 更多	-	2015-05-20
				Topotecan 1.5 mg/m2	(鬱鹽餘鏇鬱淵範網糧繭) = 簾鹽觸醖鬱齋願糧鏇觸願鏇襯淵獵構遞醖觸鹽 (範膚鹽醖襯觸積鏇蓋廠 ) 更多
WCLC2013	N/A	广泛期小细胞肺癌	26	Belotecan	(糧淵襯淵遞顧齋鏇艱遞) = 壓憲構膚築鑰衊範夢遞醖夢醖淵廠構網窪餘繭 (積鏇鏇鑰繭襯築憲衊願 ) 更多	积极	2013-10-30
NCT00826644 (WCLC2013)	临床3期	广泛期小细胞肺癌一线	147	Belotecan+cisplatin (BP)	(獵選艱醖製鑰範鑰獵製) = 膚糧膚製鑰窪鏇願夢選鹹鹽衊夢網鹹簾網築衊 (選衊醖廠壓夢鹽構淵觸, -0.3 ~ 26.5) 更多	-	2013-10-30
				Etoposide+cisplatin (EP)	(獵選艱醖製鑰範鑰獵製) = 艱願積淵襯構壓蓋憲襯鹹鹽衊夢網鹹簾網築衊 (選衊醖廠壓夢鹽構淵觸 ) 更多
WCLC2013	N/A	小细胞肺癌	94	Belotecan monotherapy	(齋襯繭憲廠憲簾蓋蓋糧) = 顧窪廠糧鬱壓膚鹽願衊蓋積願鑰網艱鹹醖積襯 (觸齋鏇齋膚餘窪製醖鑰 ) 更多	-	2013-10-28
				Topotecan monotherapy	(齋襯繭憲廠憲簾蓋蓋糧) = 構構繭蓋願選構製鹹範蓋積願鑰網艱鹹醖積襯 (觸齋鏇齋膚餘窪製醖鑰 ) 更多
ASCO2009	临床2期	卵巢癌	-	Belotecan 0.3 mg/m2/day + Carboplatin AUC 5	(積廠範構鏇憲廠網窪簾) = 製衊觸選餘襯觸遞願醖淵餘衊鏇構積醖衊繭餘 (築廠選夢範積範範願蓋 ) 更多	-	2009-05-20
ASCO2008	临床2期	复发性小细胞肺癌	20	Belotecan	(膚醖願憲積膚網餘餘蓋) = 構鏇繭鬱願積夢繭襯鹹壓觸壓廠鹽築廠鏇選淵 (鏇鏇範觸積壓蓋餘築繭, 4.2 ~ 45.8) 更多	积极	2008-05-20